![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents including VXM01, which is being developed for the treatment of glioblastoma, license the requisite manufacturing patents, and will take over existing contracts with collaborators and partners.
Lead Product(s): Necvax Neo 1
Therapeutic Area: Oncology Product Name: Necvax Neo 1
Highest Development Status: Preclinical Product Type: Vaccine
Recipient: Vaximm AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 08, 2022